The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia

Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton’s tyrosine kinase inhibitor ibrutinib compared to younger patients. It is not known whether the same holds true for the B-cell lymphoma 2 inhibitor venetoclax. We provide a co...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Haematol
Päätekijät: Eyre, Toby A., Roeker, Lindsey E., Fox, Christopher P., Gohill, Satyen H., Walewska, Renata, Walter, Harriet S., Forconi, Francesco, Broom, Angus, Arumainathan, Arvind, Brander, Danielle M., Allan, John N., Schuster, Stephen J., Hill, Brian T., Lansigan, Frederick, Cheson, Bruce D., Lamanna, Nicole, Coombs, Catherine C., Barr, Paul M., Skarbnik, Alan P., Shadman, Mazyar, Ujjani, Chaitra S., Pearson, Laurie, Pagel, John M., Jacobs, Ryan, Mato, Anthony R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7528953/
https://ncbi.nlm.nih.gov/pubmed/31682002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16271
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia